Panbela Announces Validation Of European Patent In UK, Italy, Germany, France, And Spain For Claims Of A Novel Process For The Production Of SBP-101
Portfolio Pulse from Benzinga Newsdesk
Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the validation of its European patent for a novel process for the production of SBP-101 in the UK, Italy, Germany, France, and Spain. The patent, developed in collaboration with Syngene International Ltd., reduces the number of synthetic steps from seventeen to six. The patent is valid until 2039 and covers a shorter synthesis of SBP-101, which provides a scalable, efficient, and cost-effective manufacturing process.
October 31, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The validation of Panbela's European patent for the production of SBP-101 in several countries could potentially boost the company's market position and future commercialization efforts.
The validation of the patent in multiple European countries expands the potential market for Panbela's SBP-101. The patent, which simplifies the production process, could also make the drug more cost-effective to produce, potentially improving profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100